title: Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
authors.affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria. guntram.schernthaner@meduniwien.ac.at
authors.forename: Guntram
authors.initials: G
authors.lastname: Schernthaner
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Currie
authors.forename: Gerit-Holger
authors.initials: GH
authors.lastname: Schernthaner
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077205:Pioglitazone; D018570:Risk Assessment; D012307:Risk Factors; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone